Autopsy report · NCT00332280

Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo

“Lack of efficacy. Stopped at first interim evaluation point”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 3 years 10 months before it stopped.
• 67 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

Auron Healthcare GmbH

Sponsor type

Industry

Conditions

Gastrointestinal Cancer; Prostate Cancer; Genital Neoplasms, Female

Interventions

AMT2003

Participants

67

Sites

2

Countries

Bosnia and Herzegovina, Germany

Trials that died the same way

• A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
  “Lack of efficacy determined at interim analysis” (85% match in meaning)
• Hydroxyurea in Primary Progressive Multiple Sclerosis
  “No efficacy (interim.analysis)” (81% match in meaning)
• A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
  “Interim assessment: Lack of efficacy” (78% match in meaning)
• A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
  “Lack of efficacy” (77% match in meaning)
• Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
  “Study was terminated early due to a lack of improved efficacy.” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.